Nifty Next 50 61473.55 (1.33)
Nifty Pharma 20461.9 (2.43)
Nifty Smallcap 100 15696.1 (2.88)
SENSEX 75157.26 (1.77)
Nifty 50 22828.55 (1.92)
Nifty Bank 51002.35 (1.52)
Nifty IT 32740.85 (0.69)
Nifty Midcap 100 50501.5 (1.85)
NIKKEI 225 33982.36 (1.18)
HANG SENG 21417.4 (2.40)
S&P 5449.97 (1.22)
(Including Management Discussion and Analysis Report)
Your Directors have pleasure in presenting the 66th Annual Report together with the Audited Financial Statements for the financial year ended March 31, 2024.
Financial Results:
(Rs. in lakhs)
2023-24
(a) Continuing Operations
9,717.90
Less: Depreciation
1,305.87
Profit before Tax
8,412.03
Less: Tax expense:
2,210.00
(82.16)
2,127.84
Profit after Tax from Continuing
6,284.19
Operations
(b) Discontinued Operations
(Human Pharma Undertaking)
–
Less: Tax Expense
Profit after Tax from
Discontinued Operations
Profit after Tax [(a)+(b)]
Surplus Account:
82,677.40
Add: Profit for the year
6,198.21
(85.98)
Total
88,875.61
Less: Dividend Paid
1,413.03
Net Surplus
87,462.58
Review of Performance:
During the year under review, Revenue from Operations amounted to Rs.752.79 crores as against the previous year's figure of Rs.725.11 crores, a growth of around 4%. Pre-Tax Profit for the year stood at Rs.84.12 crores as against the previous year's figure of Rs.61.64 crores. The higher profit was partly due to increase in operating profit and also due to the increase in the interest earned on the fixed deposits made from the sale proceeds of the Human Pharma Division.
A detailed review is presented under the Section "Segmentwise Performance".
Dividend:
Your Directors are pleased to recommend a dividend of Rs.10/- (100%) per Equity Share of Rs.10/- each for the year ended March 31, 2024. [Previous Year - Rs.10.00 (100%) per Equity Share of Rs.10/- each]. The dividend pay-out is in accordance with the Company's Dividend Distribution Policy.
Share Capital:
The Paid-up Equity Share Capital as on March 31, 2024 was Rs.1,413.03 lakhs. Your Company has not issued any shares with differential voting rights nor granted stock options nor sweat equity.